文献速递药疹与重症皮肤不良反应

抗骨质疏松药物诱发重症皮肤不良反应的风险及其与HLA的关联

The risk of anti-osteoporotic agent-induced severe cutaneous adverse drug reactions and their association with HLA.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-12-25

本研究纳入台湾和香港16例抗骨质疏松药物相关皮肤不良反应患者(10例重症,6例斑丘疹),分析临床特征、HLA等位基因及体外检测,并进行文献综述和Meta分析。结果显示雷奈酸锶是亚洲人群中最常见的致病药物,雷奈酸锶所致SJS与HLA-A*33:03显著相关(Pc=5.17×10-3,OR=25.97),Meta分析支持该关联(P=5.01×10-5),淋巴细胞活化试验敏感性为83.3%。

要点

  • 雷奈酸锶是亚洲人群抗骨质疏松药物相关重症药疹最常见病因。
  • HLA-A*33:03与雷奈酸锶所致SJS显著相关,OR为25.97。
  • 淋巴细胞活化试验有助于识别雷奈酸锶所致SJS的致病药物。

核心结论

  • 雷奈酸锶是抗骨质疏松药物中最常引起重症皮肤不良反应的药物。
  • HLA-A*33:03等位基因和淋巴细胞活化试验可能有助于雷奈酸锶所致重症药疹的诊断。

研究设计与样本

  • 研究纳入台湾和香港16例抗骨质疏松药物相关皮肤不良反应患者,包括10例重症药疹(8例SJS,2例DRESS)和6例斑丘疹。
  • 分析临床特征、结局、HLA等位基因和体外检测,并进行文献综述和Meta分析。

主要发现

  • 雷奈酸锶是亚洲人群中抗骨质疏松药物相关重症药疹最常见的致病药物。
  • 雷奈酸锶所致重症药疹与其他抗骨质疏松药物无交叉过敏。
  • 雷奈酸锶所致SJS与HLA-A*33:03显著相关(Pc=5.17×10-3,OR=25.97,95%CI:3.08-219.33)。
  • Meta分析显示HLA-A*33:03与亚洲人雷奈酸锶所致SJS相关(P=5.01×10-5,敏感性85.7%)。
  • 淋巴细胞活化试验识别雷奈酸锶所致SJS致病药物的敏感性为83.3%。

关键数值与推荐

  • HLA-A*33:03与雷奈酸锶所致SJS关联的Pc=5.17×10-3,OR=25.97(95%CI:3.08-219.33)。
  • Meta分析中HLA-A*33:03与亚洲人雷奈酸锶所致SJS关联的P=5.01×10-5,敏感性85.7%。
  • 淋巴细胞活化试验对雷奈酸锶所致SJS的敏感性为83.3%。

临床怎么用

  • 对服用雷奈酸锶后出现疑似重症药疹的患者,可考虑检测HLA-A*33:03。
  • 在多重用药情况下,淋巴细胞活化试验可能辅助识别雷奈酸锶为致病药物。
  • 雷奈酸锶所致重症药疹患者可考虑换用其他抗骨质疏松药物,因无交叉过敏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is increasing use of anti-osteoporotic agents (AOA) worldwide for prevention or management of patients with osteoporosis. However, there have been reports of severe cutaneous adverse reactions (SCAR) induced by AOA. A recent study showed weak association between HLA and strontium ranelate (SR)-SCAR. OBJECTIVE: To characterize patients with AOA-SCAR and investigate the HLA association and utility of in vitro diagnostic methods. METHODS: We enrolled 16 cases with AOA-cutaneous adverse drug reactions (cADR), including SCAR (n = 10: 8 with Stevens-Johnson syndrome [SJS] and 2 with drug rash with eosinophilia and systemic symptoms [DRESS]) and maculopapular exanthema (MPE) (n = 6) from Taiwan and Hong Kong. We analysed the clinical characteristics, outcomes, HLA alleles and in vitro testing of AOA-SCAR, and tolerability to alternative drugs. We further performed literature review and meta-analysis on the HLA association of AOA-SCAR. RESULTS: Our data showed strontium ranelate is the most common causality of AOA-SCAR in Asian populations. There was no cross-hypersensitivity of SR-SCAR with other AOA. HLA genotyping showed that SR-SJS was most significantly associated with HLA-A*33:03 (Pc = 5.17 × 10-3 , OR: 25.97, 95% CI: 3.08-219.33). Meta-analysis showed that HLA-A*33:03 was associated with SR-SJS (P = 5.01 × 10-5 ; sensitivity: 85.7%) in Asians. The sensitivity of lymphocyte activation test (LAT) for identifying the culprit drug of SR-SJS was 83.3%. CONCLUSIONS: Strontium ranelate is identified as the most notorious AOA associated with SCAR. The HLA-A*33:03 genetic allele and LAT testing may add benefits to the diagnosis of SR-SCAR in patients whose reaction developed while taking multiple drugs.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Chen CB, Chen YE, Chu MT, et al. The risk of anti-osteoporotic agent-induced severe cutaneous adverse drug reactions and their association with HLA. J Eur Acad Dermatol Venereol. 2020. PMID: 32896010. doi:10.1111/jdv.16924

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。